KevinAndrewDavidMD

PubMed

• Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
  Pallawi Torka, Tatyana Feldman, Kerry J Savage, Nivetha Ganesan, Esther Drill
  Journal of Clinical Oncology. 2024-12-11
• Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes.
  Jennifer K Lue, Efrat Luttwak, Alfredo Rivas-Delgado, Helen Irawan, Alexander Boardman
  Blood Cancer Journal. 2024-10-14
• 4 citations
  Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy.
  Reem Karmali, Rushad Machhi, Narendranath Epperla, Geoffrey Shouse, Jason Romancik
  Blood Advances. 2024-05-28

Abstracts/Posters

• Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma
  Kevin A. David, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0408
  Kevin A. David, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
  Kevin A. David, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
  Kevin A. David, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
  Kevin A. David, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
  Kevin A. David, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
  Kevin A. David, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malig... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018